Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
1 - 10 of 74
- Druglike FAPIs with maximal target residence time: chemical discovery and biological characterization.From1 Jan 2024 → TodayFunding: IOF - technology concept exploration
- Potent intra-tumoral autophagy blocking with kinase PROTACs and inhibitors.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Directed optimization of highly selective DPP9 inhibitors for chemical biology and translational research.From1 Nov 2023 → TodayFunding: FWO fellowships
- Cell-type specific delivery of autophagy inducers as a strategy to address localized autophagy impairment in diseaseFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Characterization and validation of novel autophagy inducers identified via high-throughput screening: a therapeutic option for the treatment of advanced atherosclerosis.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- AUTAC- and PROTAC-mediated degradation of DPP9 to induce pyroptosis: a novel treatment strategy in acute myeloid leukemia.From1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- Development of a pancreatic cancer drug-nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure (PaCaNano).From1 Sep 2023 → TodayFunding: FWO research project (including WEAVE projects)
- OncoProToolsFrom1 Jun 2023 → TodayFunding: BOF - projects
- DPP9 degradation-induced pyroptosis for treatment of acute myeloid leukemia (DPP9-TACDrug).From1 Apr 2023 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Diagnostic and theranostic targeting of fibroblast activation protein (FAP) with goed nanoparticles decorated with FAPIs and FAPI fragments.From1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
41 - 50 of 128
- Efforts towards an on‐target version of the Groebke‐Blackburn‐Bienaymé (GBB) reaction for discovery of druglike urokinase (uPA) inhibitors(2019)
Authors: Rafaela Gladysz, Johannes Vrijdag, Dries Van Rompaey, Anne-Marie Lambeir, Koen Augustyns, Hans De Winter, Pieter Van Der Veken
Pages: 12380 - 12393 - ClpP protease, a promising antimicrobial target(2019)
Authors: Carlos Moreno Cinos, Kenneth Goossens, Irene Garcìa Salado, Pieter Van Der Veken, Hans De Winter, Koen Augustyns
- Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives(2018)
Authors: Irene Garcìa Salado, Adrienn Baán, Tomas Verdeyen, An Matheeussen, Guy Caljon, Pieter Van Der Veken, Filip Kiekens, Koen Augustyns
Pages: 18 - 26 - Tozasertib analogues as inhibitors of necroptotic cell death(2018)
Authors: Sam Hofmans, Lars Devisscher, Sofie Martens, Dries Van Rompaey, Kenneth Goossens, Tatyana Divert, Wim Nerinckx, Nozomi Takahashi, Hans De Winter, Pieter Van Der Veken, et al.
Pages: 1895 - 1920 - Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy(2018)
Authors: Lars Devisscher, Samaya Van Coillie, Sam Hofmans, Dries Van Rompaey, Kenneth Goossens, Eline Meul, Hans De Winter, Pieter Van Der Veken, Peter Vandenabeele, Tom Vanden Berghe, et al.
Pages: 10126 - 10140 - Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis(2018)
Authors: Isabelle Coornaert, Sam Hofmans, Lars Devisscher, Koen Augustyns, Pieter Van Der Veken, Guido De Meyer, Wim Martinet
Pages: 477 - 488 - Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome(2018)
Authors: Hannah Ceuleers, Nikita Hanning, Leen Heirbaut, Samuel Van Remoortel, Jurgen Joossens, Pieter Van Der Veken, Sven Francque, Michelle De bruyn, Joris De Man, Jean-Pierre Timmermans, et al.
Pages: 3516 - 3533 - Identification and profiling of hydantoins(2018)
Authors: Maciej Rogacki, Eleni Pitta, Sophie Huss, Eva Maria Lopez-Roman, Argyrides Argyrou, Delia Blanco-Ruano, Monica Cacho, Koen Augustyns, Lluis Ballell, David Barros, et al.
Pages: 11221 - 11249 - Novel triazine dimers with potent antitrypanosomal activity(2018)
Authors: Muthusamy Venkatraj, Irene Garcìa Salado, Jan Heeres, Jurgen Joossens, Guy Caljon, Louis Maes, Pieter Van Der Veken, Koen Augustyns
Pages: 306 - 319 - Carboxylate isosteres for caspase inhibitors(2017)
Authors: Yves Adriaenssens, D. Jiménez Fernández, L. Vande Walle, Filipe Elvas, Jurgen Joossens, Anne-Marie Lambeir, Koen Augustyns, M. Lamkanfi, Pieter Van Der Veken
Pages: 7456 - 7473
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)